Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969 (IMAGE)

InSilico Medicine

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969

Caption

Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969. ISM8969 is a potentially best-in-class, orally available, brain-penetrant small-molecule inhibitor of the NLRP3 inflammasome being developed to treat chronic neuroinflammation and central nervous system (CNS) disorders, including Parkinson’s disease.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.